Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 8/20 | 0.77 |
| ▸ | PIM1 | P11309 | 2/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504421 | 1.00 | ESRRA (0.77) | ESRRAPIM1PIM2MAPTMCL1 | |
| SCHEMBL8271091 | 0.87 | ESRRA (1.00) | ESRRAPIM1PIM2MAPTMCL1 | |
| SCHEMBL5507657 | 0.87 | ESRRA (1.00) | ESRRAPIM1PIM2MAPTMCL1 | |
| SCHEMBL5507653 | 0.87 | ESRRA (1.00) | ESRRAPIM1PIM2MAPTMCL1 | |
| SCHEMBL5505362 | 0.83 | ESRRA (0.78) | ESRRAPIM1PIM2MAPTMCL1 | |
| SCHEMBL8271633 | 0.83 | ESRRA (0.78) | ESRRAPIM1PIM2MAPTMCL1 | |
| SCHEMBL5505359 | 0.83 | ESRRA (0.78) | ESRRAPIM1PIM2MAPTMCL1 | |
| SCHEMBL13846830 | 0.82 | ADAMTS5 (0.69) | ESRRAHPGDCISD1GSK3B | |
| SCHEMBL31090851 | 0.79 | LMNA (0.62) | MAPTNPSR1MEN1ALDH1A1LMNA | |
| SCHEMBL14677574 | 0.79 | LMNA (0.62) | MAPTNPSR1MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | claimed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | claimed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | claimed |
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | ESR2, ESRRG, GPER1 | ESRRA 5/4885PIM1 4500/4885PIM2 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.